Loading clinical trials...
Loading clinical trials...
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and s...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novo Nordisk A/S
NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more
NCT06819917 · Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, and more
NCT06661655 · Metabolic Syndrome X, Fatty Liver, and more
NCT03151473 · Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
NCT06519448 · Non-alcoholic Steatohepatitis, Liver Diseases, and more
Altasciences Company Inc.
Montreal, Quebec
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions